Software as a Medical Device (SaMD) for Cardiology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The software as a medical device for cardiology market size is expected to increase from USD 24.88 billion in 2025 to USD 28.67 billion in 2026 and reach USD 58.30 billion by 2031, growing at a CAGR of 15.25% over 2026-2031. This report is Segmented by Product Type (Diagnostic, Monitoring, Clinical Decision Support, Therapeutic), Clinical Application (Arrhythmia Detection, CAD Assessment, Heart Failure Management, and More), Deployment Model (Cloud-Based, On-Premise, Hybrid), End User (Hospitals, Cardiology Clinics, Ambulatory Care, and More), and Geography (North America, Europe, and More). Market Forecasts in Value (USD).

Global Software As A Medical Device (SaMD) For Cardiology Market Trends and Insights

Regulatory Push Is Creating a First-Mover Reimbursement Moat

Regulatory momentum is giving the Software as a Medical Device (SaMD) for Cardiology market a faster route from approval to revenue. FDA cardiology AI and ML clearances rose to 92 in 2025 from 62 in 2024, widening the pool of tools ready for deployment. Eight of the 2025 clearances included a Predetermined Change Control Plan, which allows post-market algorithm updates within an approved framework. This gives early-cleared vendors an advantage in improving performance with live clinical data while staying within the approved regulatory pathway.

Reimbursement Expansion Is the Demand Unlock the Market Was Waiting For

Payment expansion is removing one of the last major barriers in the Software as a Medical Device (SaMD) for Cardiology market. CMS made CPT code 75577 effective on January 1, 2026, with a USD 950.50 hospital outpatient payment for AI-enabled coronary plaque analysis from CCTA. CMS also created code G0680 for AI-based coronary artery calcium and aortic valve calcium analysis on chest CT, while trade reporting showed a USD 128.90 national Medicare payment rate for AI-enabled ECG analysis under CPT codes 0764T and 0765T. Predictable payment is helping hospitals and outpatient sites link software adoption to a defined reimbursement pathway.

Thin Clinical Evidence Is the Structural Vulnerability Beneath the Clearance Headline

Evidence quality remains a key constraint in the Software as a Medical Device (SaMD) for Cardiology market. A 2026 review of 277 FDA-cleared cardiology AI and ML devices found that bench studies accounted for 69.3% of validation studies, while prospective multicenter clinical trials accounted for only 3.2%. The same review reported a high risk of predicate creep in 52.2% of cleared cardiology AI devices, raising concerns over how far newer claims had moved from the original validated use case. CMS had already applied strict procedural criteria in LCD L39881 for AI-enabled coronary plaque analysis, showing that reimbursement can tighten as evidence standards rise. Vendors with broader multi-site validation and cleaner clinical datasets are better positioned to defend coverage and pricing as scrutiny increases.

Other drivers and restraints analyzed in the detailed report include:

• The Arrhythmia Detection Burden Is Larger Than Reported Incidence Suggests
• Remote Cardiac Monitoring Is Shifting Clinical Gravity from Hospitals to the Home
• Cybersecurity Incidents Are Reshaping the Risk Calculus for Payers and Providers

Segment Analysis

Diagnostic SaMD held 38.65% of the Software as a Medical Device (SaMD) for Cardiology market share in 2025, making it the foundation of current revenue. Its leadership reflected the smooth integration of diagnostic outputs into established cardiology workflows, especially in imaging-led hospital settings. In 2025, coronary CT tools alone accounted for 9 plaque quantification clearances, 7 calcium scoring clearances, and 3 FFR-derived clearances in the United States. This concentration kept diagnostic software closely aligned with routine ordering patterns, reimbursement use, and physician acceptance.

Monitoring SaMD is projected to grow at a CAGR of 18.93% from 2026 to 2031, making it the fastest-growing product type in the Software as a Medical Device (SaMD) for Cardiology market size. Growth is moving beyond simple ambulatory ECG patches toward software that combines ECG, impedance, and activity data in a single monitoring stream. Clinical decision support tools are also gaining traction as payment models begin to reward specific outputs, such as AI-enabled ECG interpretation, rather than only raw signal review. Therapeutic software remains the smallest product group as regulators continue to take a cautious approach to closed-loop or therapy-adjusting cardiac applications.

Arrhythmia detection accounted for 35.23% of the clinical application mix in 2025, keeping it at the center of current spending. The segment benefited from a large undiagnosed population, a longer history of cleared rhythm tools, and clearer reimbursement visibility than many newer cardiac applications. Hospitals and ambulatory rhythm programs already understood how to use ECG-based software, which reduced adoption friction. This installed base also allowed arrhythmia tools to become the first software layer within broader digital cardiology strategies.

Heart failure management is forecast to grow at a CAGR of 19.67% through 2031, giving it the fastest expansion profile within the Software as a Medical Device (SaMD) for Cardiology market. Remote hemodynamic monitoring, AI-driven risk stratification, and the ongoing need to reduce readmissions across health systems support this growth. Coronary artery disease assessment is also advancing after reimbursement support for AI-enabled plaque analysis, although the patent dispute between HeartFlow and Cleerly showed intensifying competition in this sub-segment. Structural heart disease assessment and cardiac imaging analysis continue to benefit from automation that reduces manual review time and supports standardized interpretation.

Complete Report Scope:

• By Product Type
  • Diagnostic SaMD
  • Monitoring SaMD
  • Clinical Decision Support SaMD
  • Therapeutic SaMD
• By Clinical Application
  • Arrhythmia Detection
  • Coronary Artery Disease Assessment
  • Heart Failure Management
  • Structural Heart Disease Assessment
  • Cardiac Imaging Analysis
• By Deployment Model
  • Cloud-Based
  • On-Premise
  • Hybrid
• By End User
  • Hospitals and Health Systems
  • Cardiology Clinics
  • Ambulatory Care Centers
  • Home Healthcare and Remote Monitoring Providers
  • Diagnostic Imaging Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.56% of the Software as a Medical Device (SaMD) for Cardiology market share in 2025, maintaining its global lead. The United States moved faster than other countries on reimbursement, with separate Medicare payment pathways in place for AI-enabled coronary plaque analysis, ECG analysis, and calcium analysis. This payment clarity supported commercial scale for pure-play vendors and imaging incumbents. The region also benefited from a large installed hospital base, while Canada and Mexico advanced despite reimbursement frameworks trailing the United States.

Asia-Pacific is projected to grow at a 17.56% CAGR from 2026 to 2031, making it the fastest-growing regional bloc in the Software as a Medical Device (SaMD) for Cardiology market. Growth is being driven by cardiovascular disease burden, national digitization efforts, and stronger regulatory alignment across major countries. Japan and South Korea are advancing with clearer product approvals, while China is attracting investment that links procedural hardware with software-enabled cardiac workflows. India and Southeast Asia remain earlier in adoption, where public health digitization programs are shaping near-term demand more than private reimbursement.

Europe held the third-largest regional share in 2025, with Germany, the United Kingdom, and France forming the main demand base. A stricter compliance environment is raising entry and product maintenance requirements while favoring vendors with stronger regulatory depth. The Middle East and Africa are still earlier in adoption, but Gulf markets are using FDA and CE pathways as reference points for local registration and early procurement. South America is gradually building its position as Brazil and Argentina work on reimbursement frameworks for AI diagnostics.

List of Companies Covered in this Report:

• AliveCor
• Anumana, Inc.
• Apple
• Boston Scientific
• Canon
• Cardiac Insight, Inc.
• Cardiologs Technologies SAS
• Cleerly, Inc.
• Eko Health, Inc.
• GE HealthCare Technologies Inc.
• HeartBeam, Inc.
• HeartFlow, Inc.
• iRhythm Technologies
• Koninklijke Philips
• Medicalgorithmics S.A.
• Medtronic
• Samsung Group
• Siemens Healthineers
• Ultromics Limited
• Viz.ai, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support